March 15, 2015 – FDA issues Drug Safety Communication regarding an increased risk of diabetic ketoacidosis (DKA, Diabetic Acidosis, Metabolic Acidosis, Ketoacidosis) associated with SGLT2 inhibitor diabetes drugs like Invokana.
March 15, 2015 – FDA issues Drug Safety Communication regarding an increased risk of diabetic ketoacidosis (DKA, Diabetic Acidosis, Metabolic Acidosis, Ketoacidosis) associated with SGLT2 inhibitor diabetes drugs like Invokana.